KRAS mutations are one of the most common oncogenic driver mutations in human cancers. including non-small cell lung cancer (NSCLC). and have established roles in cancer pathogenesis and therapeutic resistance. The development of effective inhibitors of mutant KRAS represents a significant challenge. https://cuttingedgecutleryco.shop/product-category/can-opener/